# This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).

> **NCT06738277** · PHASE1 · COMPLETED · sponsor: **Biocon Biologics UK Ltd** · enrollment: 186 (actual)

## Conditions studied

- Moderate to Severe Chronic Plaque Psoriasis

## Interventions

- **DRUG:** Bmab 1200 (Biosimilar Ustekinumab)

## Key facts

- **NCT ID:** NCT06738277
- **Lead sponsor:** Biocon Biologics UK Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-09
- **Primary completion:** 2025-07-12
- **Final completion:** 2025-07-12
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06738277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06738277, "This is Comparative Study in Normal Healthy Subjects to Evaluate Pharmacokinetics, Safety, Tolerability of Bmab 1200 -Autoinjector (AI) After Single Subcutaneous Injection (45 mg) in Comparison With Bmab 1200 -Prefilled Syringe (PFS).". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06738277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*